BB&T Securities LLC decreased its stake in Shire PLC (NASDAQ:SHPG) by 16.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,257 shares of the biopharmaceutical company’s stock after selling 6,376 shares during the period. BB&T Securities LLC’s holdings in Shire were worth $5,003,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. Commerzbank Aktiengesellschaft FI increased its stake in shares of Shire by 22.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 375 shares during the period. ETRADE Capital Management LLC increased its stake in shares of Shire by 6.9% in the fourth quarter. ETRADE Capital Management LLC now owns 7,212 shares of the biopharmaceutical company’s stock valued at $1,119,000 after buying an additional 466 shares during the period. Hills Bank & Trust Co. increased its stake in shares of Shire by 12.2% in the fourth quarter. Hills Bank & Trust Co. now owns 5,960 shares of the biopharmaceutical company’s stock valued at $924,000 after buying an additional 647 shares during the period. Putnam FL Investment Management Co. increased its stake in shares of Shire by 9.9% in the fourth quarter. Putnam FL Investment Management Co. now owns 7,442 shares of the biopharmaceutical company’s stock valued at $1,154,000 after buying an additional 670 shares during the period. Finally, SeaCrest Wealth Management LLC acquired a new stake in shares of Shire in the fourth quarter valued at about $107,000. 19.59% of the stock is owned by institutional investors.
Shire stock opened at $128.72 on Thursday. Shire PLC has a fifty-two week low of $123.73 and a fifty-two week high of $192.15. The company has a quick ratio of 0.55, a current ratio of 0.97 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $39,221.02, a P/E ratio of 9.16, a PEG ratio of 0.75 and a beta of 1.44.
Shire (NASDAQ:SHPG) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.86 by $0.12. Shire had a return on equity of 14.19% and a net margin of 28.17%. The company had revenue of $4.14 billion for the quarter. During the same quarter in the prior year, the business earned $3.37 EPS. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. sell-side analysts forecast that Shire PLC will post 15.23 EPS for the current fiscal year.
The business also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be issued a $0.8937 dividend. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is a positive change from Shire’s previous semiannual dividend of $0.15. Shire’s dividend payout ratio (DPR) is currently 7.47%.
Several brokerages have recently weighed in on SHPG. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a “buy” rating in a research note on Wednesday, March 7th. BidaskClub raised Shire from a “strong sell” rating to a “sell” rating in a research note on Friday, March 2nd. SunTrust Banks decreased their price target on Shire to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Shire in a research note on Tuesday, February 20th. Finally, Royal Bank of Canada decreased their target price on Shire to $181.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. Shire presently has a consensus rating of “Buy” and an average target price of $204.00.
ILLEGAL ACTIVITY NOTICE: “BB&T Securities LLC Reduces Holdings in Shire PLC (SHPG)” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2018/03/22/bbt-securities-llc-reduces-holdings-in-shire-plc-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.